The CEO of Regencell expresses his goal of the com
Post# of 25471
(Total Views: 157)
Posted On: 09/19/2022 7:25:23 AM
The CEO of Regencell expresses his goal of the company, his vision for the future, and his insights, to change the way patients are treated.
As a result of the prolonged health crisis and rising political unrest, market and economic performance have been on the verge of a recession for the past few months, which has weighed on investor mood. In addition, some experts believe that the combination of the Federal Reserve raising interest rates and the nation's spiraling inflation, which has reached yet another 40-year high, is a surefire prescription for a recession.
Despite all these financial difficulties, several industries have been trying to entice investors with innovative strategies as businesses increase their impact and market domination.
Many investors have recently made sizable investments on the biotechnology and bioscience industry, willing to take a chance on some of the shares in their portfolio to help stabilise their position in the case of a recession. A Mckinsey research report from 2022 claims that biotech companies raised more than $34 billion globally in 2021, more than double the $16 billion raised in 2020.
According to the same study, even while the pandemic gripped the world economy for the most of 2020, venture capital companies continued to spend more than $52 billion in therapeutic-based biotech startups between 2019 and 2021.
Yat-Gai Au, the founder and CEO of Regencell Bioscience, has made purchases of ordinary company shares from the open market since Regencell was listed on NASDAQ in mid-July 2021 in an attempt to deal with the short and disrupted investing schemes used on the company's stocks, which over time can have a negative impact on overall stock performance. Yat-Gai Au explained why he is fully devoted to this plan and the future of the company, having already invested millions of his personal funds to purchase company shares.
https://www.ibtimes.com/regencell-ceo-shares-...ed-3600337
As a result of the prolonged health crisis and rising political unrest, market and economic performance have been on the verge of a recession for the past few months, which has weighed on investor mood. In addition, some experts believe that the combination of the Federal Reserve raising interest rates and the nation's spiraling inflation, which has reached yet another 40-year high, is a surefire prescription for a recession.
Despite all these financial difficulties, several industries have been trying to entice investors with innovative strategies as businesses increase their impact and market domination.
Many investors have recently made sizable investments on the biotechnology and bioscience industry, willing to take a chance on some of the shares in their portfolio to help stabilise their position in the case of a recession. A Mckinsey research report from 2022 claims that biotech companies raised more than $34 billion globally in 2021, more than double the $16 billion raised in 2020.
According to the same study, even while the pandemic gripped the world economy for the most of 2020, venture capital companies continued to spend more than $52 billion in therapeutic-based biotech startups between 2019 and 2021.
Yat-Gai Au, the founder and CEO of Regencell Bioscience, has made purchases of ordinary company shares from the open market since Regencell was listed on NASDAQ in mid-July 2021 in an attempt to deal with the short and disrupted investing schemes used on the company's stocks, which over time can have a negative impact on overall stock performance. Yat-Gai Au explained why he is fully devoted to this plan and the future of the company, having already invested millions of his personal funds to purchase company shares.
https://www.ibtimes.com/regencell-ceo-shares-...ed-3600337
(0)
(0)